Intangible Assets

9 Months Ended

Sep. 30, 2015

3. Intangible Assets

Intangible assets consist solely of core developed technology acquired as part of a 2007 asset purchase agreement with Parivid LLC. See Part I, Item 1 “Business—Collaborations, Licenses and Asset Purchases—Parivid” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 for relevant disclosures. The developed technology intangible assets are being amortized over the estimated useful life of the Enoxaparin Sodium Injection and Glatopa developed technologies of approximately 10 years. As of September 30, 2015 and December 31, 2014, intangible assets, net of accumulated amortization, were as follows (in thousands):

	September 30, 2015							December 31, 2014
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Value		Gross Carrying Amount		Accumulated Amortization			Net Carrying Value
Total intangible assets for core and developed technology and non-compete agreement	$	10,427	$	(6,634	)	$	3,793	$	10,427	$	(5,838	)	$	4,589

The weighted-average amortization period for the Company’s intangible assets is 10 years. Amortization is computed using the straight-line method over the useful lives of the respective intangible assets as there is no other pattern of use that is reasonably estimable. Amortization expense was approximately $0.3 million for each of the three months ended September 30, 2015 and 2014, and $0.8 million for each of the nine months ended September 30, 2015 and 2014.

The Company expects to incur amortization expense of approximately $1.1 million per year for each of the next three years and $0.6 million in the fourth year.